PCVX News and Press, Vaxcyte Inc. From 01/29/26

2026-01-29 22:30:00 ET The following segment was excerpted from the Harbor Small Cap Growth Fund ( HASGX ) Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

2026-01-29 16:20:24 ET More on Vaxcyte Vaxcyte: Financial Durability And The Case For Disruption Vaxcyte, Inc. (PCVX) Presents at Jefferies London Healthcare Conference 2025 - Slideshow Vaxcyte, Inc. (PCVX) Presents at Jefferies London Healthcare Conference 2025 Tran...

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants. All shares of common stock and pre-fu...

2026-01-26 09:19:21 ET Fast Facts About the Direxion Daily S&P Biotech Bear 3x Shares ETF Read the full article on Seeking Alpha For further details see: LABD: ETF To Benefit From Downturns In The Biotech Industry

VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults Previously Vaccinated with Pneumococcal Vaccines (OPUS-3) in First Quarter of 2026 ...

2025-12-16 09:26:48 ET ... Read the full article on Seeking Alpha For further details see: Vaxcyte: Financial Durability And The Case For Disruption

Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive (PCV21) an...

2025-11-19 05:22:04 ET David Risinger from Leerink Partners issued a price target of $77.00 for PCVX on 2025-11-19 10:23:00. The adjusted price target was set to $77.00. At the time of the announcement, PCVX was trading at $49.53. The overall price target consensus is at...

2025-11-04 17:23:31 ET More on Vaxcyte Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript ClearBridge SMID Cap Growth Strategy adds CRDO, RKLB, exits OSCR, RARE Vaxcyte teams up with Thermo Fisher to ensure future vaccine production ...

Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study Modified VAX-31 Infant Phase 2 Dose-Finding Study Advanced to ...